基金管理人：嘉实基金管理有限公司 基金托管人：招商证券股份有限公司 二〇二五年七月 重要提示 1、嘉实中证港股通高股息投资交易型开放式指数证券投资基金发起式联接基金（以下简称"本基金"） 经中国证监会2025年6月6日证监许可〔2025〕1187号《关于准予嘉实中证港股通高股息投资交易型开放 式指数证券投资基金发起式联接基金注册的批复》注册募集。 2、本基金是契约型开放式ETF联接基金。 基金简称：嘉实中证港股通高股息投资ETF发起联接A，基金代码：024705，收取认（申）购费 基金简称：嘉实中证港股通高股息投资ETF发起联接C，基金代码：024706，不收取认（申）购费，但 从本类别基金资产中计提销售服务费 3、本基金的管理人为嘉实基金管理有限公司（以下简称"本公司"），托管人为招商证券股份有限公 司，注册登记机构为本公司。 4、本基金募集对象是符合法律法规规定的可投资于证券投资基金的个人投资者、机构投资者、合格境 外投资者和发起资金提供方以及法律法规或中国证监会允许购买证券投资基金的其他投资人。 5、本基金自2025年7月7日至2025年7月18日通过各销售机构公开发售。 6、发起资金的认购： 本基金发 ...

Group 1 - The core viewpoint is that the Hong Kong Stock Connect high dividend sector has significant allocation value during a weak US dollar cycle, benefiting from liquidity premium and enhanced EPS expectations for Chinese companies [1] - The depreciation of the US dollar reduces foreign exchange risks for foreign investors holding Hong Kong stocks, further elevating risk appetite [1] - In the current market environment, stable dividends remain a core selection, with traditional industry leaders expected to deliver improved dividend yields and ROE due to enhanced competition and weakened capital expenditure [1] Group 2 - The Hong Kong Stock Connect high dividend index, compiled by China Securities Index Co., selects 30 high dividend stocks from eligible Hong Kong-listed companies, focusing on those with good liquidity and consistent dividend payouts [1] - The index primarily covers traditional advantageous industries such as real estate and energy, reflecting the overall performance of high dividend securities in the Hong Kong market [1] - Investors without stock accounts can consider the Cathay China Securities Hong Kong Stock Connect High Dividend Investment ETF linked A (022274) and linked C (022275) [1]

Core Viewpoint - The Hang Seng High Dividend Yield Index (HSSCHKY) has shown positive performance, with significant increases in constituent stocks, indicating a favorable outlook for the banking sector and potential investment opportunities in high-dividend stocks [1][5]. Group 1: ETF Performance - The latest size of the Bosera Hang Seng High Dividend ETF (513690) reached 4.147 billion [2]. - Over the past two years, the net value of the Bosera Hang Seng High Dividend ETF has increased by 33.82%, ranking it in the top 5.90% among 2,219 index equity funds [2]. - The ETF has achieved a maximum monthly return of 24.18% since its inception, with an average monthly return of 4.96% during rising months [2]. Group 2: Risk and Return Metrics - As of June 27, 2025, the Sharpe ratio for the Bosera Hang Seng High Dividend ETF over the past year was 1.49 [3]. - The ETF has experienced a relative drawdown of 0.39% year-to-date compared to its benchmark, with a recovery period of 37 days [3]. Group 3: Fees and Tracking Accuracy - The management fee for the Bosera Hang Seng High Dividend ETF is 0.50%, and the custody fee is 0.10% [4]. - The tracking error for the ETF over the past six months was 0.069%, indicating a close alignment with the Hang Seng High Dividend Yield Index [5]. Group 4: Index Composition - The top ten weighted stocks in the Hang Seng High Dividend Yield Index account for 28.24% of the index, with notable companies including Yanzhou Coal Mining (01171) and Hang Lung Properties (00101) [5].

证券研究报告 科技 关注科技公司港股二次上市的投资机会 华泰研究 2025 年 7 月 02 日│中国内地 专题研究 科技 增持 (维持) | 黄乐平，PhD | 研究员 | | --- | --- | | SAC No. S0570521050001 | huangleping@htsc.com | | SFC No. AUZ066 | +(852) 3658 6000 | | 陈旭东 | 研究员 | | SAC No. S0570521070004 | chenxudong@htsc.com | | SFC No. BPH392 | +(86) 21 2897 2228 | | 于可熠 | 研究员 | SAC No. S0570525030001 SFC No. BVF938 行业走势图 (11) 4 20 35 50 Jul-24 Oct-24 Feb-25 Jun-25 (%) 科技 沪深300 近期，港股市场出现了 A 股已上市科技公司密集赴港二次上市的新趋势。截 至 6 月 30 日，2025 年已有包括蓝思科技、龙旗科技、豪威集团等在内 16 家 A 股半导体/消费电子公司提交了港股招股书，数量 ...

以下文章来源于申万宏源证券上海分公司 ，作者李金玲 申万宏源证券上海分公司 . 申万宏源证券上海分公司官微，能为您提供账户开立、软件下载、研究所及投顾资讯等综合服务，为您 的财富保驾护航。 数据速看： 2. 融资融券数据： 当前市场融资融券余额为18384.93亿元，较上期上升0.94%，其中融资 余额18265.53亿元，融券余额119.40亿元。本期两融日均交易额为1185.69亿元，较上期上 升9.77%，其中融资日均净买入1180.65亿元，较两周前上升9.79%，融券日均净卖出5.04 亿元，较上期上升5.54%。近两周融资净买入前三的行业分别为计算机、银行和非银金融； 融券净卖出前三的行业分别为非银金融、银行和石油石化。 3. 涨跌情况： 近两周全市场上涨家数高于下跌家数，近两周涨幅前三的行业为通信、计算机 和电子，跌幅前三的行业为美容护理、石油石化和医药生物。 4. 强弱分析： 近两周全部A股强弱分析得分为5.97，沪深300强弱分析得分5.83，创业板强 弱分析得分6.28，科创板强弱分析得分6.40，处于中性区间。 测量结果：健康 诊断说明： 本周上证综指向上突破3月高点，但当下行情距牛市启 ...

Core Insights - The core investment theme for the first half of 2025 revolves around opportunities in the Hong Kong stock market and the recovery of the pharmaceutical sector [1][2][3] Fund Performance - The top-performing fund for the first half of 2025 is the Huatai-PineBridge Hong Kong Advantage Select A, achieving a return of 85.64% [2][3] - Other notable funds include CITIC Construction Investment North Exchange Select Two-Year Open A with a return of 82.45% and Great Wall Pharmaceutical Industry Select A with a return of 75.18% [2][3] - Among the top ten funds, six are from CITIC Construction Investment, Huaxia, and Great Wall, focusing on the North Exchange or pharmaceutical sectors, all exceeding a 66% return [3] Pharmaceutical Sector Highlights - The pharmaceutical and biotechnology sectors have shown strong performance, with various funds achieving significant returns, such as the Bank of China Hong Kong Stock Connect Pharmaceutical A at 70.08% and Ping An Pharmaceutical Select A at 58.80% [4][5] - The overall pharmaceutical index has risen by 26.74% year-to-date, with the innovative drug sector outperforming, showing a year-to-date increase of 24.83% [5][6] Market Dynamics - The Hong Kong stock market, particularly in the innovative drug sector, has become a focal point for investors, with the Hong Kong Stock Connect Innovative Drug Index showing a year-to-date increase of over 60% [7][9] - The innovative drug sector is expected to continue attracting investment due to favorable policies and commercial acceleration, with significant transactions in the sector reaching $45.5 billion in the first five months of the year [6][9] Future Outlook - The investment strategy for the second half of 2025 is anticipated to focus on growth sectors, particularly innovative drugs, with three main investment themes identified: commercialization in the domestic medical insurance market, international licensing of domestic innovative drugs, and capitalizing on industry cycles and valuation opportunities [4][5] - The overall valuation of the innovative drug sector remains reasonable, providing potential opportunities for investment despite previous market corrections [5][9]

海富通基金指出，港股估值当前处于历史相对低位，估值绝对水平远低于美欧日市场水平，性价比相对 较高。 汇添富基金表示，下半年港股走势或呈现"震荡上行+结构分化"格局。核心驱动因素包括宏观政策将聚 焦高质量发展、科技创新与内需提振，叠加稳增长政策加码，有望推动港股基本面修复；全年南向资金 净流入或突破万亿元规模，持续改善港股流动性。同时，海外区域性资金对港股关注度上升，若基本面 持续改善，外资配置比例有望从当前的低位逐步回升。 华夏基金认为，在国内经济复苏、AI业绩催化预期以及更多优质企业赴港上市的背景下，下半年恒生 科技的估值有望持续提升。而一旦有爆点事件催化，高弹性、高成长等特性也使其具备更大的向上动 能。 恒生指数高开0.96%，恒生科技指数涨1.07%。银河娱乐涨超9%，金沙中国涨6%，吉利汽车涨近5%。 关于港股后市 光大证券称，短期在流动性较难继续放松的背景下，结合A股财报披露扰动、中美关系仍有不确定性等 事件对风险偏好可能有所压制，港股市场可能呈现震荡走势。长期来看，港股整体盈利能力相对较强， 同时互联网、新消费、创新药等资产相对稀缺，结合当前估值仍偏低，长期配置性价比仍较高。 中信证券表示，在港股 ...

景林资产发给高净值客户的沟通信指出：香港市场成为今年上半年IPO融资第一的股票市场是一个重要 的信号。国际资本放弃了之前对中国资产的偏见，重新回到香港这个国际金融中心和投资中国的桥头 堡。叠加大量南下资金的涌入，港股进入了活跃和繁荣的时代。（资事堂） ...

转自：新华财经 记者了解到，借着这一轮港股IPO热潮，内资证券公司正加快"走出去"，更好地服务企业跨境融资需 求。与此前外资机构主导格局不同，在港股IPO市场中，内资机构近期逐步走上"C"位。接受采访的多 位专家表示，助力企业赴港上市考验的是证券公司的综合服务能力，证券公司需提高在不同市场中的 IPO服务能力、并购重组能力、引入资本能力。 券商7月"金股"名单近期陆续出炉。数据显示，截至7月1日记者发稿时，已有超过200只A股及港股标的 入围券商7月"金股"名单，恺英网络、紫金矿业、沪电股份、牧原股份等标的关注度较高，香港交易 所、心动公司等港股标的也获得券商青睐。券商此前推荐的6月"金股"超六成在当月取得正收益，国元 证券、申万宏源推荐的部分标的涨幅明显。对于A股市场7月表现，券商人士研判其将延续震荡态势， 配置上看好高景气产业结构性机会；港股后市或也呈现震荡走势，配置上可继续采取"哑铃"策略，关注 科技成长及高股息板块。 7月1日，A股迎来下半年首个交易日。截至收盘，创新药、银行、有色金属等板块走势活跃，舒泰神、 昂利康、建设银行、浦发银行等多只股票创历史新高；A股市场成交额为1.5万亿元，在没有北向资金 ...

Core Viewpoint - The Hong Kong stock market has seen a significant increase in share buybacks in the first half of the year, with nearly 230 companies participating, indicating a strong response to market conditions and a commitment to future growth [1][2]. Group 1: Share Buyback Trends - Nearly 230 Hong Kong companies have conducted share buybacks as of June 30, showing a notable year-on-year increase [1]. - Major sectors involved in buybacks include internet technology and financial blue chips, with companies like HSBC, Tencent, and AIA leading in total buyback amounts [1]. - Tencent Holdings has been particularly active, repurchasing shares for a total of 36.54 billion HKD, averaging 500 million HKD per day over 31 trading days [2]. Group 2: Performance of Buyback Companies - Companies like Meituan, Kuaishou, and Xiaomi have also engaged in significant buybacks, with Meituan repurchasing shares worth 392 million HKD on May 27 [2]. - As of June 30, Xiaomi's stock has increased by 73.77%, Kuaishou by 53.08%, and Tencent by 21.68%, indicating a positive market response to these buybacks [2]. - Analysts suggest that undervalued internet stocks in Hong Kong have potential for further appreciation due to strong fundamentals and market support [2]. Group 3: Consumer Sector Buybacks - The consumer sector has seen new entrants in share buybacks, including Anta Sports, Bosideng, and Mengniu Dairy, with Anta repurchasing nearly 1 billion HKD worth of shares over seven trading days in January [3]. - Bosideng has repurchased approximately 260 million HKD worth of shares, with a stock price increase of 19.59% year-to-date [3]. - Analysts believe that Anta Sports is well-positioned for long-term growth in the global sports market due to its competitive advantages [3]. Group 4: Broader Market Impact - Other consumer companies, such as Zhou Hei Ya and Andeli Juice, have also increased their buyback efforts, with Zhou Hei Ya's total reaching 187 million HKD [4]. - The biopharmaceutical sector has seen significant buybacks as well, with companies like WuXi Biologics and Fosun Pharma participating [4]. - The overall buyback trend has contributed to a positive market sentiment, with the Hang Seng Index and Hang Seng Tech Index rising by 20% and 18.68% respectively this year [4].